CN1568370A - 用d－氨基酸氧化酶和d－天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍 - Google Patents

用d－氨基酸氧化酶和d－天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍 Download PDF

Info

Publication number
CN1568370A
CN1568370A CNA028066650A CN02806665A CN1568370A CN 1568370 A CN1568370 A CN 1568370A CN A028066650 A CNA028066650 A CN A028066650A CN 02806665 A CN02806665 A CN 02806665A CN 1568370 A CN1568370 A CN 1568370A
Authority
CN
China
Prior art keywords
amino
acid
alkyl
oxidase
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028066650A
Other languages
English (en)
Chinese (zh)
Inventor
D·科恩
I·丘马科夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of CN1568370A publication Critical patent/CN1568370A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
CNA028066650A 2001-01-16 2002-01-15 用d－氨基酸氧化酶和d－天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍 Pending CN1568370A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US60/261,883 2001-01-16
US30544501P 2001-07-13 2001-07-13
US60/305,445 2001-07-13
US34521101P 2001-10-22 2001-10-22
US60/345,211 2001-10-22
US33388101P 2001-11-19 2001-11-19
US60/333,881 2001-11-19

Publications (1)

Publication Number Publication Date
CN1568370A true CN1568370A (zh) 2005-01-19

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028066650A Pending CN1568370A (zh) 2001-01-16 2002-01-15 用d－氨基酸氧化酶和d－天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍

Country Status (11)

Country Link
EP (1) EP1412515A2 (https=)
JP (1) JP2004537275A (https=)
KR (1) KR20030066813A (https=)
CN (1) CN1568370A (https=)
AU (1) AU2002247939B2 (https=)
BR (1) BR0206495A (https=)
CA (1) CA2433866A1 (https=)
EA (1) EA006654B1 (https=)
IL (1) IL156865A0 (https=)
MX (1) MXPA03006321A (https=)
WO (1) WO2002066672A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108504752A (zh) * 2018-06-26 2018-09-07 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907A (zh) * 2020-07-08 2020-11-10 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60228954D1 (en) 2001-05-03 2008-10-30 Galileo Lab Inc Pyruvatderivate
WO2003070743A1 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20060234221A1 (en) * 2001-12-12 2006-10-19 Genset S.A. Biallelic markers of d-amino acid oxidase and uses thereof
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
JP2007517056A (ja) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
JP5367377B2 (ja) * 2006-01-09 2013-12-11 オクラホマ メディカル リサーチ ファウンデーション 炎症性疾患治療のためのランチオニン関連化合物
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP1165836A2 (en) * 1999-03-30 2002-01-02 Genset Schizophrenia associated genes, proteins and biallelic markers
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108504752A (zh) * 2018-06-26 2018-09-07 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN108504752B (zh) * 2018-06-26 2021-05-11 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907A (zh) * 2020-07-08 2020-11-10 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用
CN111909907B (zh) * 2020-07-08 2022-05-24 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Also Published As

Publication number Publication date
AU2002247939B9 (en) 2002-09-04
JP2004537275A (ja) 2004-12-16
EA200300807A1 (ru) 2004-08-26
EP1412515A2 (en) 2004-04-28
BR0206495A (pt) 2006-01-24
WO2002066672A2 (en) 2002-08-29
IL156865A0 (en) 2004-02-08
WO2002066672A3 (en) 2004-02-26
KR20030066813A (ko) 2003-08-09
MXPA03006321A (es) 2003-10-06
CA2433866A1 (en) 2002-08-29
EA006654B1 (ru) 2006-02-24
AU2002247939B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CN1568370A (zh) 用d－氨基酸氧化酶和d－天冬氨酸氧化酶拮抗剂治疗中枢神经系统障碍
US20030185754A1 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
Xu et al. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder
CN101238222B (zh) 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体
KR101178463B1 (ko) 와파린의 감도를 예측하는 유전적 변이체
KR20170041907A (ko) 매니폴드 및 초평면을 이용한 생물학적 데이터의 컴퓨터 분석법
Steinberger et al. Heterozygous mutation in 5’-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia
CN107602690B (zh) 肺动脉高压相关的ptgis基因突变及其应用
CA2483105C (en) Autoimmune conditions and nadph oxidase defects
Chen et al. Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives
Ogawa et al. GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men
US20040254363A1 (en) Genes and snps associated with eating disorders
US20030166554A1 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
Purevsuren et al. Clinical and molecular aspects of Japanese patients with mitochondrial trifunctional protein deficiency
AU2002339698B2 (en) Biallelic markers of D-amino acid oxidase and uses thereof
Veiga-da-Cunha et al. Mutations in the glucokinase regulatory protein gene in 2p23 in obese French caucasians: M. Veiga-da-Cunha et al.: Mutation in glucokinase regulatory protein
Fruhman et al. Atypical presentation of Leigh syndrome associated with a Leber hereditary optic neuropathy primary mitochondrial DNA mutation
CA2561669A1 (en) Methods for identifying risk of osteoarthritis and treatments thereof
CN114277123B (zh) 与精神分裂症相关的含有snp位点的多核苷酸和用途
Yang et al. A novel homozygous nonsense mutation in the CA2 gene (c. 368G> A, p. W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family
HK1072445A (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
KR101114033B1 (ko) 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법
Pawłowicz et al. Coincidence of PTPN22 c. 1858CC and FCRL3‐169CC genotypes as a biomarker of preserved residual β‐cell function in children with type 1 diabetes
TW202310854A (zh) 用於減少ｔａｕ表現之方法
WO2009037481A1 (en) Methods for diagnosing and treating dementia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072445

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1072445

Country of ref document: HK